Procter & Gamble Health Profit & Loss Annual

BSE: 500126 | NSE: PGHL | ISIN: INE199A01012 | Sector: Biotechnology & Drugs

5,279.85 +122.30 (2.37%)Updated : 09 Oct 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Jun 24	Jun 23
Total Operating Expense	973.03	632.47	892.85	933.04
Other Net	5.28	3.31	3.63	3.01
Diluted Weighted Average Shares	1.66	1.66	1.66	1.66
Gain( Loss)on Saleof Assets	-1.87	-	0.00	0.71
Depreciation/ Amortization	23.29	16.30	27.05	27.76
Operating Income	434.94	301.70	258.41	296.58
Net Income	326.91	234.41	200.98	229.47
Income Availableto Com Excl Extra Ord	326.91	234.41	200.98	229.47
Other Operating Expenses Total	14.40	4.73	16.09	16.63
Net Income Before Taxes	449.86	311.62	273.32	314.20
Interest Exp( Inc) Net- Operating Total	0.30	0.39	0.35	0.34
Net Income After Taxes	326.91	234.41	200.98	229.47
Income Availableto Com Incl Extra Ord	326.91	234.41	200.98	229.47
Costof Revenue Total	461.89	317.51	408.72	447.18
Gross Profit	946.08	616.66	742.54	782.44
Interest Inc( Exp) Net- Non- Op Total	11.51	6.61	11.28	13.90
Diluted Net Income	326.91	234.41	200.98	229.47
DPS- Common Stock Primary Issue	155.00	125.00	110.00	95.00
Provisionfor Income Taxes	122.95	77.21	72.34	84.73
period Type	-	-	-	-
Net Income Before Extra Items	326.91	234.41	200.98	229.47
Total Revenue	1,407.97	934.17	1,151.26	1,229.62
period Length	12.00	9.00	12.00	12.00
Revenue	1,407.97	934.17	1,151.26	1,229.62
Selling/ General/ Admin Expenses Total	465.79	288.82	413.89	423.49
Diluted Normalized EPS	197.76	141.95	131.22	143.18
Research Development	7.36	2.61	3.86	5.71
Diluted EPS Excluding Extra Ord Items	196.94	141.00	121.08	138.24
Unusual Expense( Income)	-	2.11	22.89	11.93